ChemInform Abstract: Pulmonary Drugs and Genes Delivery Systems for Lung Disease Treatment

ChemInform ◽  
2014 ◽  
Vol 45 (17) ◽  
pp. no-no
Author(s):  
Caina Xu ◽  
Huayu Tian ◽  
Xuesi Chen
2014 ◽  
Vol 32 (1) ◽  
pp. 13-21 ◽  
Author(s):  
Caina Xu ◽  
Huayu Tian ◽  
Xuesi Chen

2020 ◽  
Vol 21 (17) ◽  
pp. 6380 ◽  
Author(s):  
Gengqi Liu ◽  
Jonathan F. Lovell ◽  
Lei Zhang ◽  
Yumiao Zhang

Stimulus-responsive drug delivery systems generally aim to release the active pharmaceutical ingredient (API) in response to specific conditions and have recently been explored for disease treatments. These approaches can also be extended to molecular imaging to report on disease diagnosis and management. The stimuli used for activation are based on differences between the environment of the diseased or targeted sites, and normal tissues. Endogenous stimuli include pH, redox reactions, enzymatic activity, temperature and others. Exogenous site-specific stimuli include the use of magnetic fields, light, ultrasound and others. These endogenous or exogenous stimuli lead to structural changes or cleavage of the cargo carrier, leading to release of the API. A wide variety of stimulus-responsive systems have been developed—responsive to both a single stimulus or multiple stimuli—and represent a theranostic tool for disease treatment. In this review, stimuli commonly used in the development of theranostic nanoplatforms are enumerated. An emphasis on chemical structure and property relationships is provided, aiming to focus on insights for the design of stimulus-responsive delivery systems. Several examples of theranostic applications of these stimulus-responsive nanomedicines are discussed.


2006 ◽  
Vol 2 (6) ◽  
pp. 849-852 ◽  
Author(s):  
Steffan Schulz ◽  
Lindsay Bischoff ◽  
David Michel ◽  
Chris T Derk

2020 ◽  
Vol 11 (44) ◽  
pp. 6988-7008 ◽  
Author(s):  
Duc Dung Nguyen ◽  
Jui-Yang Lai

Recent exploitations of stimuli-responsive polymers as ophthalmic drug delivery systems for the treatment of eye diseases are summarized and discussed.


2017 ◽  
Vol 38 (12) ◽  
pp. 1259-1261 ◽  
Author(s):  
Burcin Celik ◽  
Muzaffer Elmali ◽  
Okan Gulel ◽  
Mustafa Demirag

2021 ◽  
pp. 1-19
Author(s):  
Larissa Spósito ◽  
Giovanna Capaldi Fortunato ◽  
Bruna Almeida Furquim de Camargo ◽  
Matheus Aparecido dos Santos Ramos ◽  
Maurício Palmeira Chaves de Souza ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Li Duan ◽  
Kan Ouyang ◽  
Xiao Xu ◽  
Limei Xu ◽  
Caining Wen ◽  
...  

The emerging clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated system (Cas) gene-editing system represents a promising tool for genome manipulation. However, its low intracellular delivery efficiency severely compromises its use and potency for clinical applications. Nanocarriers, such as liposomes, polymers, and inorganic nanoparticles, have shown great potential for gene delivery. The remarkable development of nanoparticles as non-viral carriers for the delivery of the CRISPR/Cas9 system has shown great promise for therapeutic applications. In this review, we briefly summarize the delivery components of the CRISPR/Cas9 system and report on the progress of nano-system development for CRISPR/Cas9 delivery. We also compare the advantages of various nano-delivery systems and their applications to deliver CRISPR/Cas9 for disease treatment. Nano-delivery systems can be modified to fulfill the tasks of targeting cells or tissues. We primarily emphasize the novel exosome-based CRISPR/Cas9 delivery system. Overall, we review the challenges, development trends, and application prospects of nanoparticle-based technology for CRISPR/Cas9 delivery.


Sign in / Sign up

Export Citation Format

Share Document